DE69925256D1 - Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen - Google Patents

Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen

Info

Publication number
DE69925256D1
DE69925256D1 DE69925256T DE69925256T DE69925256D1 DE 69925256 D1 DE69925256 D1 DE 69925256D1 DE 69925256 T DE69925256 T DE 69925256T DE 69925256 T DE69925256 T DE 69925256T DE 69925256 D1 DE69925256 D1 DE 69925256D1
Authority
DE
Germany
Prior art keywords
trisubstituted
treatment
triazine derivatives
hiv infections
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69925256T
Other languages
English (en)
Other versions
DE69925256T2 (de
Inventor
Frans Daeyaert
Corte Bart De
Jonge Rene De
Jan Heeres
Yung Ho
Adriaan Janssen
W Kavash
Maria Koymans
Joseph Kukla
William Ludovici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69925256D1 publication Critical patent/DE69925256D1/de
Application granted granted Critical
Publication of DE69925256T2 publication Critical patent/DE69925256T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69925256T 1998-03-27 1999-03-24 Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen Expired - Fee Related DE69925256T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7963398P 1998-03-27 1998-03-27
US79633P 1998-03-27
EP98201589 1998-05-14
EP98201589A EP0945447A1 (de) 1998-03-27 1998-05-14 Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
PCT/EP1999/002044 WO1999050256A1 (en) 1998-03-27 1999-03-24 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Publications (2)

Publication Number Publication Date
DE69925256D1 true DE69925256D1 (de) 2005-06-16
DE69925256T2 DE69925256T2 (de) 2006-02-23

Family

ID=22151790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925256T Expired - Fee Related DE69925256T2 (de) 1998-03-27 1999-03-24 Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen

Country Status (33)

Country Link
US (3) US6150360A (de)
EP (2) EP0945447A1 (de)
JP (1) JP2002511390A (de)
KR (1) KR100593396B1 (de)
CN (1) CN1157386C (de)
AP (1) AP1475A (de)
AR (1) AR018169A1 (de)
AT (1) ATE295355T1 (de)
AU (1) AU758624C (de)
BG (1) BG64903B1 (de)
BR (1) BR9909197A (de)
CA (1) CA2324921C (de)
DE (1) DE69925256T2 (de)
DK (1) DK1066269T3 (de)
EA (1) EA004540B1 (de)
EE (1) EE200000535A (de)
ES (1) ES2243056T3 (de)
HK (1) HK1032394A1 (de)
HR (1) HRP20000621A2 (de)
HU (1) HUP0101372A3 (de)
ID (1) ID26043A (de)
IL (1) IL138670A (de)
NO (1) NO317425B1 (de)
NZ (1) NZ506787A (de)
OA (1) OA11493A (de)
PL (1) PL194660B1 (de)
PT (1) PT1066269E (de)
SI (1) SI1066269T1 (de)
SK (1) SK14052000A3 (de)
TR (1) TR200002761T2 (de)
TW (1) TW570917B (de)
WO (1) WO1999050256A1 (de)
ZA (1) ZA200006042B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
US6645964B1 (en) * 1999-11-29 2003-11-11 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agent
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
EP1282606B1 (de) 2000-05-08 2015-04-22 Janssen Pharmaceutica NV Hiv replications hemmende pyrimidinen und triazinen
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
US6858608B2 (en) * 2001-01-09 2005-02-22 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) * 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7112587B2 (en) * 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003024926A2 (en) * 2001-09-21 2003-03-27 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) * 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) * 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
EP1441683A4 (de) * 2001-10-12 2005-10-26 Univ New York Trisubstituierte triazin-verbindungen und verfahren zur herstellung und verwendung der verbindungen mit antitubulin-wirkung
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
PT1479397E (pt) * 2002-02-05 2011-09-01 Astellas Pharma Inc Derivados de 2,4,6-triamino-1,3,5-triazina
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
US20070232572A1 (en) * 2003-02-07 2007-10-04 Aventis Pharma S.A. Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
AU2004213173B2 (en) * 2003-02-07 2010-07-29 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazines
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
US6875781B2 (en) 2003-04-04 2005-04-05 Cell Therapeutics, Inc. Pyridines and uses thereof
ES2667668T3 (es) 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
CA2533397A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
US7335770B2 (en) * 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
US7923554B2 (en) 2004-08-10 2011-04-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
AU2005288864B2 (en) 2004-09-30 2012-08-23 Janssen Sciences Ireland Uc HIV inhibiting 5-heterocyclyl pyrimidines
WO2006035069A1 (en) 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US7592451B2 (en) * 2005-06-23 2009-09-22 New York University Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
CN101245051B (zh) * 2005-12-22 2011-04-20 中国科学院上海药物研究所 2，4-二取代氨基-6-取代-[1，3，5]三嗪类化合物、其制备方法、药物组合物及用途
ES2465666T3 (es) 2006-03-30 2014-06-06 Janssen R&D Ireland Pirimidinas 5-amido-sustituidas inhibidoras del HIV
EP2114901B1 (de) 2006-12-29 2014-04-09 Janssen R&D Ireland Hiv-inhibierende 6-substituierte pyrimidine
EP2114902B1 (de) 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv-inhibierende 5,6-substituierte pyrimidine
JP6184866B2 (ja) 2010-10-27 2017-08-23 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 新規抗がん剤
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
EP3122736A1 (de) * 2014-03-28 2017-02-01 Basf Se Diaminotriazinderivate als herbizide
KR20180102590A (ko) * 2015-12-24 2018-09-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
CN111629730A (zh) 2017-08-24 2020-09-04 加利福尼亚大学董事会 眼部药物组合物
CN109053613A (zh) * 2018-07-04 2018-12-21 复旦大学 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2742466A (en) * 1956-04-17 Chx n nhx c c
US2671810A (en) * 1952-05-24 1954-03-09 Du Pont Long-chain diketones
BE754242A (fr) * 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
US4652645A (en) * 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
EP0541966A3 (en) * 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) * 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
CA2174080A1 (en) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9519197D0 (en) * 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
CA2318362A1 (en) * 1998-01-13 1999-07-22 Sharon T. Cload Triazine antiviral compounds

Also Published As

Publication number Publication date
KR100593396B1 (ko) 2006-06-28
EP0945447A1 (de) 1999-09-29
EE200000535A (et) 2002-04-15
IL138670A (en) 2005-12-18
ES2243056T3 (es) 2005-11-16
US20020115668A1 (en) 2002-08-22
AR018169A1 (es) 2001-10-31
AU758624B2 (en) 2003-03-27
ATE295355T1 (de) 2005-05-15
HRP20000621A2 (en) 2001-04-30
EP1066269B1 (de) 2005-05-11
DK1066269T3 (da) 2005-09-05
AU3599799A (en) 1999-10-18
SK14052000A3 (sk) 2001-06-11
PL343195A1 (en) 2001-07-30
EA004540B1 (ru) 2004-06-24
NO20004809L (no) 2000-11-24
HK1032394A1 (en) 2001-07-20
NO317425B1 (no) 2004-10-25
OA11493A (en) 2004-05-07
PL194660B1 (pl) 2007-06-29
ID26043A (id) 2000-11-16
US6372729B1 (en) 2002-04-16
NO20004809D0 (no) 2000-09-26
SI1066269T1 (en) 2005-10-31
HUP0101372A2 (hu) 2001-10-28
EA200000993A1 (ru) 2001-04-23
CA2324921A1 (en) 1999-10-07
US6774235B2 (en) 2004-08-10
JP2002511390A (ja) 2002-04-16
AP1475A (en) 2005-10-03
BG64903B1 (bg) 2006-08-31
KR20010034270A (ko) 2001-04-25
HUP0101372A3 (en) 2003-02-28
CA2324921C (en) 2009-05-12
CN1295566A (zh) 2001-05-16
AU758624C (en) 2004-03-11
TR200002761T2 (tr) 2001-01-22
WO1999050256A1 (en) 1999-10-07
TW570917B (en) 2004-01-11
US6150360A (en) 2000-11-21
BR9909197A (pt) 2000-12-05
CN1157386C (zh) 2004-07-14
DE69925256T2 (de) 2006-02-23
AP2000001913A0 (en) 2000-09-30
NZ506787A (en) 2003-02-28
BG104716A (en) 2001-04-30
EP1066269A1 (de) 2001-01-10
PT1066269E (pt) 2005-09-30
ZA200006042B (en) 2001-10-26

Similar Documents

Publication Publication Date Title
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60219292D1 (de) Pyrazolderivate zur behandlung von hiv
ATE304358T1 (de) (s,s)-reboxetin zur behandlung von migränekopfschmerzen
NO20021474L (no) Forbindelser for behandling av ischemi
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
DE59910146D1 (de) Topisch anwendbares arzneimittel zur behandlung von virusinfektionen
ATE316374T1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
IS6020A (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
IL138670A0 (en) Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
EA200001065A1 (ru) Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ITRM990762A0 (it) Procedimento per la preparazione di filati ondee o compensina.
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee